Janssen Zarnestra
Executive Summary
Brand name Zarnestra is chosen for the farnesyl transferase inhibitor R-115777, which is in Phase III for pancreatic cancer and relapsed, refractory or secondary acute leukemia, Johnson & Johnson says. Chemotherapy agent is in Phase II for RAS-dependent solid tumors. Zarnestra will be marketed by OrthoBiotech